Overview
Dermorphin is a heptapeptide originally isolated from the skin of South American frogs of the genus Phyllomedusa. It is a potent opioid peptide with high affinity and selectivity for the μ-opioid receptor. Unlike most naturally occurring opioid peptides, dermorphin contains a D-alanine residue at position 2.
The primary purpose of dermorphin in research is to study its analgesic properties and its interaction with the μ-opioid receptor. It serves as a valuable tool for investigating pain pathways and developing novel analgesics.
While dermorphin has been investigated for pain management, it is important to note its potential for dependence and side effects, which limit its clinical use. Research focuses on understanding its mechanism of action and exploring derivatives with improved safety profiles.
Mechanism of Action
Dermorphin exerts its analgesic effects by selectively binding to μ-opioid receptors in the central nervous system. Activation of these receptors leads to a cascade of intracellular events that inhibit neuronal excitability and reduce the transmission of pain signals. This includes the activation of G proteins, inhibition of adenylyl cyclase, and modulation of ion channels.
The high affinity of dermorphin for the μ-opioid receptor is attributed to its unique structure, including the presence of D-alanine at position 2, which confers resistance to enzymatic degradation and enhances its binding affinity. This selectivity minimizes interactions with other opioid receptors, such as δ and κ receptors, reducing the likelihood of unwanted side effects.
Key Benefits
- Potent analgesic effect
- Selective μ-opioid receptor agonist
Research & Indications
Research on dermorphin has primarily focused on its analgesic properties and its potential for pain management. Studies have shown that dermorphin is significantly more potent than morphine in relieving pain in animal models. It has been investigated for the treatment of chronic pain conditions, such as neuropathic pain and cancer pain.
However, due to its potential for dependence and side effects, dermorphin is not widely used in clinical practice. Current research efforts are directed towards developing dermorphin analogs with improved safety profiles and reduced potential for abuse.
Dosing Protocols
Disclaimer: The following dosing information is for research purposes only and should not be considered medical advice. Consult with a qualified healthcare professional before using dermorphin or any other peptide.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Pain Relief (Research) | 0.01-0.05 mg/kg | As needed | SubQ or IM |
Supplies Needed
For an 8-16 week research protocol:
- Peptide Vials: Quantity needed depends on the chosen dosage and duration. Example: 4-10 vials of 1mg each.
- Insulin Syringes (U-100): 2-3 per week, 20-40 total.
- Bacteriostatic Water: 2-3 × 10mL bottles.
- Alcohol Swabs: One for vial + one for injection site daily.
Side Effects & Safety
Common side effects of dermorphin include respiratory depression, sedation, nausea, vomiting, constipation, and dizziness. Due to its opioid activity, dermorphin has a high potential for dependence and abuse. It should be used with caution in individuals with a history of substance abuse or respiratory disorders.
Dermorphin is contraindicated in individuals with known hypersensitivity to opioids. It should not be used in combination with other central nervous system depressants, such as alcohol or benzodiazepines, due to the risk of additive respiratory depression.
Storage & Handling
Dermorphin should be stored at 2-8°C (refrigerated) in a tightly sealed container, protected from light and moisture. Prior to use, dermorphin can be reconstituted with bacteriostatic water or sterile saline. The reconstituted solution should be used immediately or stored at 2-8°C for up to 24 hours.